Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Okay. This is Marty Auster. I'm the lead mid-cap analyst at Crédit Suisse, and you are watching Alnylam at the 29th Annual Crédit Suisse Healthcare Conference, and the first and hopefully, only virtual conference. I've got John Maraganore from Alnylam, CEO. And very excited to have you here, and we were just talking in the breakout about how long you've kind of known me and I have been following Alnylam and paying attention to the name for a long time.
Catch us up on where you're at. You've had an enormous run of success in several drug approvals in the last couple of years. Maybe kind of frame where you're at now in the life cycle of Alnylam and what the vision is going forward? And kind of we'll jump off that -- from there.
Yes, sounds great, Marty. Well, first of all, thanks for having me. It's great to be here virtually. Look, Alnylam is in a really exciting
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
